Avalyn Pharmaceuticals

Avalyn Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing inhaled therapies for the treatment of rare and severe lung diseases. The company's primary focus is on improving the delivery of proven treatments for idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases (ILD) by reformulating them for inhalation. Their lead programs, AP01 (inhaled pirfenidone) and AP02 (inhaled nintedanib), aim to provide superior efficacy and better tolerability compared to existing oral therapies by delivering the drug directly to the lungs. Avalyn's approach leverages advanced nebulizer technology to optimize drug distribution and patient outcomes in pulmonary medicine. By reducing systemic exposure, the company seeks to minimize the gastrointestinal and other side effects that often lead to treatment discontinuation with oral antifibrotics. The company is currently advancing its lead candidate through mid-to-late-stage clinical trials to address the significant unmet need in the pulmonary fibrosis community.